FDA Approves Update to Neffy 1 Mg Label, Removing Age Requirement

Why It Matters

Removing the age restriction broadens access to a needle‑free epinephrine option for young children, potentially increasing market adoption and improving emergency treatment confidence among caregivers.

Key Takeaways

• Age restriction removed for neffy 1 mg.
• Weight range 33‑66 lb eligible for 1 mg dose.
• 2 mg dose recommended for patients ≥66 lb.
• Label now permits thawed or high‑temp exposure.
• Needle‑free epinephrine option expands pediatric access.

Pulse Analysis

The neffy nasal spray represents a growing segment of needle‑free emergency therapeutics, addressing long‑standing anxiety around auto‑injectors in both children and adults. By delivering epinephrine via a simple spray, it sidesteps the dexterity challenges and fear associated with traditional syringes, aligning with broader consumer preferences for user‑friendly medical devices. This shift reflects a wider industry trend toward non‑invasive delivery systems, which have gained traction in allergy management and acute care settings.

Regulatory approval to drop the four‑year age floor is significant because it aligns the product with weight‑based dosing rather than arbitrary age limits. The updated label now specifies use for patients weighing 33‑66 lb (approximately 15‑30 kg) with a 1 mg dose, while recommending a 2 mg dose for those over 66 lb. Additionally, the FDA’s relaxed storage language—allowing use after accidental freezing or exposure to temperatures up to 122 °F—reduces logistical barriers for schools, camps, and families, ensuring the device remains viable in real‑world conditions.

For ARS Pharmaceuticals, the label change unlocks a sizable pediatric market segment, estimated to comprise roughly 25 % of epinephrine users under four years old. By positioning neffy as a convenient, needle‑free alternative, the company can differentiate itself from competitors like Mylan’s EpiPen and potentially capture market share among caregivers seeking ease of administration. The free carrying case further enhances product appeal, supporting broader distribution through pharmacies, pediatric clinics, and school health programs. As awareness grows, the update may drive higher prescription volumes and reinforce ARS’s reputation for innovative allergy solutions.